The mechanism of action and chemical synthesis of FDA newly approved drug molecules

被引:0
作者
Shen, Dan-Dan [1 ]
Zhang, Yue-Lin [1 ]
Li, Xiang [1 ]
Bai, Yi-Ru [2 ]
Xiong, Jun-Feng [2 ,3 ]
Seng, Dong-Jie [2 ]
Zhang, Yao-Dong [2 ]
Liu, Hong-Min [2 ,4 ]
Yuan, Shuo [2 ,4 ]
Yang, Li [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 3, Dept Obstet & Gynecol, Zhengzhou Key Lab Endometrial Dis Prevent & Treatm, Zhengzhou 450052, Peoples R China
[2] Zhengzhou Univ, Henan Childrens Hosp, Zhengzhou Childrens Hosp, Childrens Hosp,Dept Pharm, Zhengzhou 450018, Peoples R China
[3] Shanxi Med Univ, Dept Biochem & Mol Biol, Taiyuan, Peoples R China
[4] Zhengzhou Univ, Sch Pharmaceut, Sch Pharmaceut Sci & Key Lab Adv Drug Preparat Tec, Zhengzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
chemical synthesis; clinical application; drug design; mechanism of action; small molecule drug; PRECLINICAL CHARACTERIZATION; ARTIFICIAL-INTELLIGENCE; DISCOVERY; INHIBITOR; DESIGN; RECEPTOR; ANTAGONISTS; EFFICIENT; GEPIRONE; ANALOGS;
D O I
10.1002/ddr.22260
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In 2023, the U.S. Food and Drug Administration has approved 29 small molecule drugs. These newly approved small molecule drugs possess the distinct scaffolds, thereby exhibiting diverse mechanisms of action and binding modalities. Moreover, the marketed drugs have always been an important source of new drug development and creative inspiration, thereby fostering analogous endeavors in drug discovery that potentially extend to the diverse clinical indications. Therefore, conducting a comprehensive evaluation of drug approval experience and associated information will facilitate the expedited identification of highly potent drug molecules. In this review, we comprehensively summarized the relevant information regarding the clinical applications, mechanisms of action and chemical synthesis of 29 small molecule drugs, with the aim of providing a promising structural basis and design inspiration for pharmaceutical chemists.
引用
收藏
页数:33
相关论文
共 74 条
[21]   Design, synthesis and biological evaluation of VEGFR-2/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat [J].
Gao, Yali ;
Li, Fei ;
Ni, Xin ;
Yang, Siwang ;
Liu, Han ;
Wu, Xingye ;
Liu, Jieqing ;
Ma, Junjie .
RSC ADVANCES, 2023, 13 (41) :28462-28480
[22]   β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs [J].
Gonzalez-Bello, Concepcion ;
Rodriguez, Diana ;
Pernas, Marina ;
Rodriguez, Angela ;
Colchon, Esther .
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (05) :1859-1881
[23]   Synthesis of proline-modified analogues of the neuroprotective agent glycyl-L-prolyl-glutamic acid (GPE) [J].
Harris, PWR ;
Brimble, MA ;
Muir, VJ ;
Lai, MYH ;
Trotter, NS ;
Callis, DJ .
TETRAHEDRON, 2005, 61 (42) :10018-10035
[24]   Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors [J].
Hoegenauer, Klemens ;
Soldermann, Nicolas ;
Zecri, Frederic ;
Strang, Ross S. ;
Grayeleau, Nadege ;
Wolf, Romain M. ;
Cooke, Nigel G. ;
Smith, Alexander B. ;
Hollingworth, Gregory J. ;
Blanz, Joachim ;
Gutmann, Sascha ;
Rummel, Gabriele ;
Littlewood-Evans, Amanda ;
Burkhart, Christoph .
ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (09) :975-980
[25]   Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II) [J].
Hoveyda, Hamid R. ;
Fraser, Graeme L. ;
Dutheuil, Guillaume ;
El Bousmaqui, Mohamed ;
Korac, Julien ;
Lenoir, Francois ;
Lapin, Alexey ;
Noel, Sophie .
ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (07) :736-740
[26]   Palovarotene inhibits the NF-κB signalling pathway to prevent heterotopic ossification [J].
Huang, Junchao ;
Wu, Jiang ;
Lin, Jialiang ;
Li, Congbin ;
Tang, Bo ;
Xiao, Haijun .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2022, 49 (08) :881-892
[27]   Further contribution to the discussion on perfluorohexyloctane eye drops in dry eye disease [J].
Jung, Verena ;
Kroesser, Sonja ;
Burian, Gabriela ;
Grillenberger, Ralf ;
Korward, Johannes ;
Roesky, Christian .
SCIENCE OF THE TOTAL ENVIRONMENT, 2024, 906
[28]   Hit discovery and hit-to-lead approaches [J].
Keseru, Gyorgy M. ;
Makara, Gergely M. .
DRUG DISCOVERY TODAY, 2006, 11 (15-16) :741-748
[29]   A sustainable synthesis of the SARS-CoV-2 Mpro inhibitor nirmatrelvir, the active ingredient in Paxlovid [J].
Kincaid, Joseph R. A. ;
Caravez, Juan C. ;
Iyer, Karthik S. ;
Kavthe, Rahul D. ;
Fleck, Nico ;
Aue, Donald H. ;
Lipshutz, Bruce H. .
COMMUNICATIONS CHEMISTRY, 2022, 5 (01)
[30]   Discovery of a Novel Class of Acylthiourea-Containing Isoxazoline Insecticides against Plutella xylostella [J].
Li, Fangyi ;
Jiang, Biaobiao ;
Luo, Yuqin ;
He, Siqi ;
Feng, Di ;
Hu, Deyu ;
Song, Runjiang .
MOLECULES, 2023, 28 (08)